Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

Overview

Journal Front Oncol

Specialty Oncology

Date 2014 Jun 25

PMID 24959421

Citations 25

Authors

Mirjam Renovanz

Ella L Kim

Affiliations

Soon will be listed here.

Citing Articles

Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation.

Wang L, Zhong S, Fan X, Xu Y, Wang M, Xu Y Redox Biol. 2025; 81:103522.

PMID: 39983342 PMC: 11893312. DOI: 10.1016/j.redox.2025.103522.

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.

Wang J, Sun N, Kunzke T, Shen J, Feuchtinger A, Wang Q Br J Cancer. 2024; 130(6):1036-1045.

PMID: 38267634 PMC: 10951255. DOI: 10.1038/s41416-023-02559-6.

Intratumoral Heterogeneity in Lung Cancer.

Lv X, Mao Z, Sun X, Liu B Cancers (Basel). 2023; 15(10).

PMID: 37345046 PMC: 10216154. DOI: 10.3390/cancers15102709.

Liquid biopsy in NSCLC: a new challenge in radiation therapy.

Perillo A, Olufemi M, De Robbio J, Mancuso R, Roscigno A, Tirozzi M Explor Target Antitumor Ther. 2022; 2(2):156-173.

PMID: 36046142 PMC: 9400754. DOI: 10.37349/etat.2021.00038.

Basket Trials: Review of Current Practice and Innovations for Future Trials.

Hobbs B, Carmagnani Pestana R, Zabor E, Kaizer A, Hong D J Clin Oncol. 2022; 40(30):3520-3528.

PMID: 35537102 PMC: 10476732. DOI: 10.1200/JCO.21.02285.

References

Logue J, Morrison D . Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012; 26(7):641-50. PMC: 3323875. DOI: 10.1101/gad.186965.112. View

Masui K, Gini B, Wykosky J, Zanca C, Mischel P, Furnari F . A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 2013; 34(4):725-38. PMC: 3616676. DOI: 10.1093/carcin/bgt086. View

Blair B, Bardelli A, Park B . Somatic alterations as the basis for resistance to targeted therapies. J Pathol. 2013; 232(2):244-54. DOI: 10.1002/path.4278. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Burrell R, McGranahan N, Bartek J, Swanton C . The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467):338-45. DOI: 10.1038/nature12625. View

Vogelstein B, Papadopoulos N, Velculescu V, Zhou S, Diaz Jr L, Kinzler K . Cancer genome landscapes. Science. 2013; 339(6127):1546-58. PMC: 3749880. DOI: 10.1126/science.1235122. View

Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins V, Marioni J . Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 110(10):4009-14. PMC: 3593922. DOI: 10.1073/pnas.1219747110. View

Mardis E . Genome sequencing and cancer. Curr Opin Genet Dev. 2012; 22(3):245-50. PMC: 3890425. DOI: 10.1016/j.gde.2012.03.005. View

Stephens P, Greenman C, Fu B, Yang F, Bignell G, Mudie L . Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144(1):27-40. PMC: 3065307. DOI: 10.1016/j.cell.2010.11.055. View

10.

Visvader J, Lindeman G . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-68. DOI: 10.1038/nrc2499. View

11.

Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

12.

Keats J, Chesi M, Egan J, Garbitt V, Palmer S, Braggio E . Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5):1067-76. PMC: 3412330. DOI: 10.1182/blood-2012-01-405985. View

13.

OBrien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004. DOI: 10.1056/NEJMoa022457. View

14.

Adams J, Kelly P, Dakic A, Carotta S, Nutt S, Strasser A . Role of "cancer stem cells" and cell survival in tumor development and maintenance. Cold Spring Harb Symp Quant Biol. 2008; 73:451-9. DOI: 10.1101/sqb.2008.73.004. View

15.

Bernards R . A missing link in genotype-directed cancer therapy. Cell. 2012; 151(3):465-8. DOI: 10.1016/j.cell.2012.10.014. View

16.

Jones S, Laskin J, Li Y, Griffith O, An J, Bilenky M . Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010; 11(8):R82. PMC: 2945784. DOI: 10.1186/gb-2010-11-8-r82. View

17.

Russnes H, Navin N, Hicks J, Borresen-Dale A . Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011; 121(10):3810-8. PMC: 3195464. DOI: 10.1172/JCI57088. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

20.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View